Otolaryngology Doctors in Vallejo, CA Accepting Medicare

6 Otolaryngology doctors found. Showing 1 - 6

Paul A. Martin, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 707-651-1000

Adnan Joseph Hadeed, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 607 Georgia Street, Vallejo, CA 94590 Phone: 707-554-8244    Fax: 707-554-1213

Suraj Kedarisetty, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 707-651-1000

Edward D. Tsong, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 707-651-1000

Laurence Ariyasu, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 707-651-1000

Marc S. Fleisher, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 707-651-1000

News Archive

Researchers create new method to analyze big data for better predictions

Researchers at Princeton, Columbia and Harvard have created a new method to analyze big data that better predicts outcomes in health care, politics and other fields.

Bariatric surgery reduces risk of heart attack, stroke or death

Bariatric surgery can cut the incidence of heart attack, stroke or death by as much as 50 percent, according to a new study presented here at the 28th Annual Meeting of the American Society for Metabolic & Bariatric Surgery.

AU health ministers highlight concerns over climate change's impact on health at CAMH5

African health ministers last week discussed their concerns about the health implications of climate change during the fifth African Union Conference of Ministers of Health in Windhoek, Namibia, PANA/Afrique en ligne reports. The conference, which focused on climate change, ended on Friday.

Genetic interactions are the key to understanding complex traits

In recent years, genetic studies have uncovered hundreds of DNA variations linked to common diseases, such as cancer or diabetes, raising the prospect that scientists can gauge disease risk based on information in an individual's genome.

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.

Read more Medical News

› Verified 8 days ago